In Brief: Psivida, Compumedics, Avantogen
Wednesday, 22 June, 2005
Psivida (ASX:PSD) has released the full results of its Phase IIa trial of BrachySil in inoperable primary liver cancer patients, showing that the product is safe and effective in prompting tumour regression.
Compumedics (ASX:CMP) has promoted Dr Curtis Ponton to vice president and chief scientist for the Compumedics Neuroscan business group following the departure of Dr Stephen Sands.
Paul Hopper, who resigned as CEO and managing director of Australian Cancer Technologies (ASX:ACU) -- now known as Avantogen -- in February, has been appointed chairman of US based biotech Innovate Oncology (OTC:IOVO), a company founded by Bioaccelerate Holdings (OTC:BACLE). Innovate Oncology owns the North American rights, with Avantogen, to RP-101, a pancreatic cancer drug currently in Phase II clinical studies.
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
